Trellus Health Secures Six-Month Contract Extension with Johnson & Johnson

Trellus Health plc announced on 18 February 2026 a six-month contract extension with Johnson & Johnson Health Care Systems to continue providing Trellus Elevate, supporting patients with moderate to severely active inflammatory bowel disease who are prescribed a J&J therapy for treatment of IBD. The collaboration with J&J, initially signed in January 2025, has been extended to mid-2026 with the same economic terms, including a fixed monthly management fee.

A key factor in the extension was the achievement of engagement and satisfaction metrics during the initial pilot phase. Based on these metrics, J&J broadened the way patients can access the enrollment channels beyond the initial pilot funnel in mid-January 2026, reflecting continued confidence in the programme's performance.

The extension provides eligible patients prescribed a J&J therapy access to Trellus Elevate, offering patients the tools and confidence to navigate the emotional and physical challenges of their conditions, staying engaged and adhering to their treatment plans.

In response to the announcement, shares in the London-based telemedicine company more than doubled to 1.02 pence each on Wednesday morning in London. The stock remains down 47% over the past year, however.

The Company also continues to move forward with its TrialSet vertical, which is being deployed into agreed-upon sites with ICON plc for an ongoing, mid-stage immunology and inflammation clinical trial sponsored by Takeda Pharmaceutical Co Ltd. Trellus is also implementing TrialSet with PSI Inc across two late-stage immunology and inflammation clinical trials sponsored by Sanofi and will be deployed into agreed-upon sites beginning mid-Q2.

The co-founder and chief executive commented that the extension of the collaboration with J&J represents further external validation of the platform and the engagement outcomes achieved during the pilot phase. Together with the rollout of TrialSet with leading CRO partners, Trellus Health operates across the full programme lifecycle, from clinical trials through commercial deployment, using its proprietary resilience methodology to support engagement and programme success. The company is establishing a scalable go-to-market model for pharma, with continued focus on disciplined execution, recurring revenue growth and expansion across immunology and inflammation.

As previously disclosed, the Company expects revenue for the year ended 2025 to be approximately $545,000 and has further reduced its monthly cash burn to approximately $400,000 by late 2025 from approximately $440,000 in October 2025. This was moderately offset by recurring monthly management fees generated during the second half of the year.

As announced previously, the Company has secured a £5 million convertible facility with Alumni Capital LLC, which was approved by shareholders on 20 January 2026. The net proceeds of the First Tranche Notes and Second Tranche Notes, totaling £737,500 in gross principal, are expected to extend the Company's cash runway into late Q1 2026. The Directors continue ongoing discussions regarding additional sources of funding to further extend the Company's cash runway, irrespective of the utilization of the Notes.

The Board remains focused on accelerating commercial momentum by expanding the Company's footprint through strategic partnerships, deepening pharmaceutical partnerships and scaling TrialSet across additional programmes and sponsors. The Directors believe the recent contract extension, combined with ongoing CRO implementations, positions the Company to build increasing recurring revenue visibility through 2026.